Notices
20 November 2017
Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO
Zobair M. Younossi, Arian Afendy, Maria Stepanova, Andrei Racila, Fatema Nader, Rachel Gomel, Ricky Safer, William R. Lenderking, Anne Skalicky, Leah Kleinman, Robert P. Myers, G. Mani Subramanian, John G. McHutchison, Cynthia Levy, Christopher L. Bowlus, Kris Kowdley, Andrew J. Muir – 20 November 2017 – Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC‐specific patient‐reported outcome (PRO) instrument.
New insights into diagnosis and therapeutic options for proliferative hepatoblastoma
- Read more about New insights into diagnosis and therapeutic options for proliferative hepatoblastoma
Katarzyna B. Hooks, Jérôme Audoux, Helena Fazli, Sarah Lesjean, Tony Ernault, Nathalie Dugot‐Senant, Thierry Leste‐Lasserre, Martin Hagedorn, Benoit Rousseau, Coralie Danet, Sophie Branchereau, Laurence Brugières, Sophie Taque, Catherine Guettier, Monique Fabre, Anne Rullier, Marie‐Annick Buendia, Thérèse Commes, Christophe F. Grosset, Anne‐Aurélie Raymond – 20 November 2017 – Surgery and cisplatin‐based treatment of hepatoblastoma (HB) currently guarantee the survival of 70%‐80% of patients.
Masthead
20 November 2017
Hepatology Highlights
Clara Tow, Robert S. Brown, Zaid Husni Tafesh, Robert E. Schwartz, Russell Rosenblatt, Shawn L. Shah, Nicole T. Shen, Aleksey Novikov, Shirley Cohen‐Mekelburg, Nicholas Russo, Vikas Gupta – 20 November 2017
2017 Hepatology referees (volumes 65 and 66)
20 November 2017
Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: More details, more significance
Youliang Pei, Xiao‐ping Chen, Wanguang Zhang – 20 November 2017
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice
Esther Nuñez‐Durán, Mariam Aghajan, Manoj Amrutkar, Silva Sütt, Emmelie Cansby, Sheri L. Booten, Andrew Watt, Marcus Ståhlman, Norbert Stefan, Hans‐Ulrich Häring, Harald Staiger, Jan Borén, Hanns‐Ulrich Marschall, Margit Mahlapuu – 20 November 2017 – Nonalcoholic fatty liver disease (NAFLD) contributes to the pathogenesis of type 2 diabetes and cardiovascular disease, and patients with nonalcoholic steatohepatitis (NASH) are also at risk of developing cirrhosis, liver failure, and hepatocellular carcinoma.
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure
Chetan Kalal, Akash Shukla, Ravi Mohanka, Mihir Vora, Priyesh Patel, Samir Shah – 20 November 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih‐Wei Lin, Yang Lei, Teresa I. Ng, Preethi Krishnan, Sarah Kopecky‐Bromberg, Jens Kort, Federico J. Mensa – 20 November 2017 – Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options.